To the editor, We carefully reviewed the ODISEA study by Linda et al. [1], in which the authors were the first to show that treatment with prolonged-release pirfenidone (PR-PFD) at a dose of 1200mg/ day for 24months significantly improved non-invasive markers of liver fibrosis, liver function, and quality of life in patients with compensated cirrhosis, with a manageable safety profile. While the authors acknowledged several study limitations, incorporating additional clinical and mechanistic considerations would further strengthen the study's depth and broader applicability.